Author Archives: admin


Teesside baby will be third in country to have ground breaking complex cancer treatment – Teesside Live

Teesside tot Olivia-Grace Corcoran was flying to London with her family today to start ground breaking treatment in a bid to cure her leukaemia.

The six month old, from Dormanstown, near Redcar, will become only the third person in the country - and the youngest - to undergo a complex and specialist treatment called CAR T cell therapy.

She was diagnosed with a form of acute leukaemia in March at the age of just four months after starting to repeatedly vomit her baby milk back up.

The beautiful little girl, who her family describe as nothing short of amazing, has already undergone chemotherapy to try to beat the disease and was due to have a stem cell transplant at Newcastle's RVI.

Instead, doctors have taken the decision to fly her to London's Great Ormond Street Hospital for the highly specialist treatment in a bid to stabilise her condition.

Her dad Jordan, 22, a plumber, and mum Chloe Kirk, 20, will fly with her to the hospital on Tuesday, June 8, for initial tests. She'll then have to spend three months in the capital whilst the complex procedure is carried out.

Jordan said he hasn't had time yet to process the enormity of the situation, instead the young family are concentrating their energy on Olivia-Grace and tackling things as they come.

"It came as a shock when they said go to London, we weren't expecting it," said Jordan.

"We thought we'd be in the RVI in Newcastle but after speaking with the doctors, they wanted to do this new therapy at Great Ormond Street Hospital.

"Olivia-Grace is fine, she's really content and she just seems to get on with things really well."

CAR T cell therapy involves taking a sample of T cells from the blood - the type of cells that fight infection and diseases. They are then taken to a lab and genetically modified to try and get them to recognise cancer cells.

Once they have grown and multiplied, the cells are then dripped back into the bloodstream. The aim is for the CAR T cells to then attack the cancer cells.

In Olivia-Grace's case, says Jordan, the initial T cells will come from an adult blood donor.

The family have been told she is only the third person to have it, and the youngest.

"It makes you wonder who thought of doing that in the first place - but whoever it was, thank you," said Jordan.

After initial bone marrow tests, the young family hope to be back on Teesside on Wednesday. From then, depending on results, Olivia-Grace will have to spend three months at the London hospital.

If the CAR T cell therapy works, the hope is she'll then be able to have a stem cell transplant as planned.

Chloe will stay with her, says Jordan, and the hope is that his mum will be able stay with them too. Jordan works full time but hopes he'll be able to travel up and down to Great Ormond Street Hospital every weekend to be with his family.

To sign up for Teesside Live news updates, go here

The Dormanstown community have already rallied round with their support by organising a number of fundraising initiatives to help the young family. You can find their GoFundMe page here.

Originally posted here:
Teesside baby will be third in country to have ground breaking complex cancer treatment - Teesside Live

Local veterinary clinics offer integrated care options for pets – williamsonherald.com

After graduating from the University of Tennessee College of Veterinary Medicine and practicing in the field for several years, Dr. Mitch McKee began to explore alternative treatment methods that would improve his four-legged patients lives, working collaboratively with conventional treatments and therapies.

McKee went on to pursue various accreditations in holistic veterinary medicine from Chi University in Reddick, Florida, including a masters degree in traditional Chinese veterinary medicine, making him one of only approximately 300 people across the country with this certification.

He now incorporates these accreditations and practices into his treatments daily for patients at both Cupola Animal Hospitals locations, including Berry Farms Animal Hospital in Franklin and Concord Road Animal Hospital in Brentwood.

Using both traditional and holistic methods of medicine allows us to provide our patients and their owners with the best of both worlds, McKee said. Western medicine is great, we love it and need it, but its more of a one-size-fits-all method. You tend to treat the problem and not the patient. With an integrated approach, Chinese methods and holistic practices allow us to individualize therapy so that we treat the underlying issue that led to the problem at hand, often with fewer side effects.

McKee and his fellow certified veterinary acupuncturist at Cupola, Dr. Ben Larson, are among just a handful of veterinarians in the Middle Tennessee area qualified to use acupuncture, and they utilize it as a treatment option regularly. Both clinics offer three types of acupuncture, which has been shown to initiate healing and decrease pain to improve a patients quality of life.

The clinics also offer chiropractic care, food therapy, massage therapy, herbal medicine, stem cell therapy, and ozone (O3) therapy in addition to acupuncture, treatment options the doctors recommend for a number of animal patients.

Any patient, regardless of age or medical issue, can benefit from these integrated therapies, McKee said. You can utilize them one time for a particular situation, or monthly, or however often you need to. Theres a great deal of flexibility with offering multiple modalities of therapy, and weve found that using them can decrease the need for expensive or risky surgeries. We have witnessed countless success stories with our patients that demonstrate these treatment options are effective and reliable.

Berry Farms Animal Hospital recently celebrated its fourth anniversary in March, and Concord Road celebrated its second anniversary last month. To learn more about the clinics or to make an appointment, visit CupolaAnimalHospitals.com.

Follow this link:
Local veterinary clinics offer integrated care options for pets - williamsonherald.com

Brave Nathaniel Nabena, 9, all smiles as he has life-saving procedure – thanks to you – The Mirror

Brave Nathaniel Nabena smiles from his hospital bed moments before a life-saving procedure.

The nine-year-old had a vital stem cell transplant at Great Ormond Street Hospital on Wednesday after Sunday People readers helped raised more than 215,000.

Nathaniel, battling acute myeloid leukaemia, was on a drip for 30 minutes as umbilical cord stem cells were fed into his body.

Afterwards, dad Ebi said: Nathaniel is very happy. It was amazing to finally get to this point we have all been waiting for.

The youngster was admitted a fortnight ago and had five doses of chemo over ten days to prepare him for the procedure.

How brave has Nathaniel been? Have your say in comments below

Mum Modupe, 38, was able to spend time with him before his transplant.

Consultants warn he faces weeks of sickness as his body reacts to the new cells with symptoms including vomiting and a fever.

Ebi, 45, said: His doctors hope to see improvements after five weeks. It is so hard to see him so exhausted but I dont have a choice. We are grateful to have this done. Our fingers are crossed to see what happens.

For now, Nathaniel has a compromised immune system and is susceptible to falling ill, so he will be staying on the ward.

Stars including Simon Cowell, David Walliams, Katie Price and JLS singer Aston Merrygold rallied to support him after we told of the desperate race to fund treatment.

Nathaniels left eye was removed in his home country of Nigeria a year ago, due to myeloid sarcoma cancer. He was diagnosed with AML in the UK in November after coming here to have a prosthetic eye fitted.

Nathaniel was told a stem-cell transplant was his only hope for survival but it would cost 201,000 as he is not a British citizen. Ebi and Modupe were initially told it could cost as much as 825,000 but the figure was revised after doctors waived their fees and offered to treat him in their own time.

The Mirror's newsletter brings you the latest news, exciting showbiz and TV stories, sport updates and essential political information.

The newsletter is emailed out first thing every morning, at 12noon and every evening.

Never miss a moment by signing up to our newsletter here.

The lad was admitted to GOSH on May 24 after generous Brits rushed to help the family raise cash.

Business analyst Ebi, who is staying at the hospitals family quarters, said: Ive been there the whole time. When he is not sleeping he is passing the time playing his games.

We sometimes talk about when he gets better and how exciting that will be. This is a difficult thing for him to go through, but Nathaniel is being brave, he is well in himself.

In acute myeloid leukaemia, unhealthy blood-forming stem cells grow quickly in the bone marrow.

This prevents it from making normal red blood cells, white blood cells and platelets meaning the body cannot fight infections or stop bleeding.

A stem cell transplant, also known as a bone marrow transplant, can help AML patients stimulate new bone marrow growth and restore the immune system.

Before treatment, patients need high doses of chemo and sometimes radiotherapy.

This destroys existing cancer and bone marrow cells and stops the immune system working, to cut the risk of transplant rejection.

In an allogeneic transplant, stem cells are taken from a family member, unrelated donor or umbilical cord blood. In Nathaniels case, it was from a cord.

They are then passed into the patients body through a line inserted in a large, central vein, in a process that takes up to two hours.

You can also remove stem cells from the patients body and transplant them later, after any damaged or diseased cells have been removed this is called an autologous transplant.

The survival rate after a transplant for patients with acute leukaemia in remission and using related donors is 55% to 68%, according to Medicine Net. If the donor is unrelated, it is 26% to 50%.

See the original post:
Brave Nathaniel Nabena, 9, all smiles as he has life-saving procedure - thanks to you - The Mirror

Blood cancer and leukaemia: UAE oncologist urges public to spot the symptoms – The National

A leading oncologist has urged the public to be aware of the symptoms of blood cancer and leukaemia amid a global rise in new cases.

Dr Shahrukh Hashmi, chair of the haematology and oncology department at Abu Dhabi's Sheikh Shakhbout Medical City, said too many cases were diagnosed in the advanced stage.

Leukaemia is a group of blood cancers that usually develop in the bone marrow and the lymphatic system.

It is among the 10 most prevalent cancers globally and according to studies has been on the rise in recent years. The five-year survival rate in the United States is about 57 per cent.

The one thing that the public can take charge of is active surveillance, with regular pap smears, colonoscopies and mammograms

Dr Shahrukh Hashmi, Sheikh Shakhbout Medical City, Abu Dhabi

We have hundreds of cases recorded every year but it is very likely that there are even more that go unrecorded, because many go underdiagnosed or misdiagnosed," said Dr Hashmi, a specialist in late-stage chemotherapy treatment and cancer survivability.

Less is known about the causes of leukaemia and lymphoma than many other cancers. Exposure to certain chemicals, genetic disorders, family history and smoking are known to be factors.

Some studies have linked blood cancers to a rise in pollution.

Dr Hashmi believes more research is needed in the Gulf and UAE to understand the causes.

He said environmental factors could play a part, along with "inheritable cancers due to consanguineous marriages".

We have not yet had any epidemiological studies giving the exact cause of the significantly higher ratio of blood cancers to solid cancers in the UAE," he said.

_______________________

- fever or chills

- persistent fatigue, weakness

- frequent or severe infections

- losing weight without trying

- swollen lymph nodes, enlarged liver or spleen

- excessive sweating, especially at night

Source: Mayo Clinic

_______________________

Dr Hashmi said too many patients shuttle between smaller hospitals and undergo a myriad of referrals before they reach a specialist cancer ward.

The biggest problem I see here is the dissipation of care. Many patients will go to several hospitals before finally landing at tertiary care centres like SSMC," he said.

By the time they come here they already have been to three or even four hospitals which delays care.

Last month, a study shed light on the high prevalence of cancer in UAE and Saudi Arabia.

The analysis of 2017 data from major developed countries showed almost half of all cancer cases in the UAE involved people aged under 50.

Dr Abdulmajeed Alzubaidi takes The National on a tour of the facilities

Abu Dhabi's new Sheikh Shakhbout Medical City opened towards the end of 2019. All photos by Chris Whiteoak / The National

A sculpture in the foyer of the sprawling hospital

The emergency department can handle hundreds of patients

The hospital is located on a large campus outside the city

A state-of-the-art surgical theatre

Floor to ceiling windows allow for plenty of natural light

The hospital is jointly run by America's top-ranked medical group - Mayo Clinic - and Abu Dhabi public hospital operator Seha

A view from outside Sheikh Shakhbout hospital

An air conditioned walk way connects hospital wings and parking facilities

The hospital's location allows for large rooms and wards

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The facility has taken over patients and services from older public hospitals

The studys authors, from University of Sharjah's College of Medicine, said the trend was a "critical issue that is currently underreported".

As with global trends, breast cancer was most prevalent accounting for 36 per cent of all cases followed by several forms of colorectal cancers.

The latter in particular is closely linked to lifestyle choices, including bad diet, smoking and drinking alcohol.

Dr Hashmi said better lifestyles, high public awareness and regular screening of people of all ages will save lives.

"The one thing that the public can take charge of when it comes to cancer is active surveillance," he said.

"People should get regular screenings for cancers such as pap smears, colonoscopies and mammograms. These are preventative measures that have been around for decades in Europe and the US.

"Our screening rates are low and we are really hoping it can go up, especially for the most common cancer we know of, breast cancer.

For blood cancers, some of the common symptoms are fatigue and persistent swollen lymph nodes.

Acute leukaemia patients will generally need a bone marrow or stem cell transplant.

Despite advances in the UAE's organ transplant programme, including the first bone marrow transplant in 2020, many patients travel abroad for treatment.

Sheikh Shakhbout Medical City will have its own transplant centre set up by the final three months of 2021.

For patients such as 34-year-old Mohammad Hoda, an electrician who works for a company in Abu Dhabi, it cannot open too soon.

He is undergoing chemotherapy at SSMC and his doctors are working with hospitals in India to try to find a suitable donor for a bone marrow transplant.

The Indian father-of-four was found with advanced leukaemia just over a month ago.

"I was feeling very tired and had severe pain in my body. I also had a few nose bleeds," he said.

When The National visited his hospital room last week, he was hopeful that medics in India will find a match, giving a thumbs up as he posed for a photograph.

But like all organ transplant patients, has no way of knowing if and how long it could take to find a donor.

"It is hard that I am alone here without my family, and my future is uncertain," he said.

View original post here:
Blood cancer and leukaemia: UAE oncologist urges public to spot the symptoms - The National

Replotting the human: the thorny ethics of growing babies outside the womb – Prospect

In its worthy pursuit of what the philosopher Francis Bacon called the relief of mans estate, science has a habit of creating previously unknown moral dilemmas. Thats nowhere more apparent than in the sciences pertaining to the beginning of human lives.

When IVF took off after the birth of Louise Brown in 1978, fertility doctors were faced with the question of what to do with embryos produced in vitrothat is, outside the wombwhich would not, either because of their unviability or sheer excess in number, be implanted for gestation. Many were donated for embryological research, which has made huge strides as a result. But this has also complicated the already impassioned argumentsstill unresolvedabout the moral status of the human embryo.

Similar wrangles loom over the recent report in Nature by a team of scientists based in Israel who say that they can gestate mouse embryos in glass jars for up to 12 days. That might not sound long, but it is half a mouses normal gestation period: the embryos can reach a stage where the internal organs are in place, the heart is beating, and the hind legs are developing.

By contrast, no human embryos have been grown outside the womb beyond 14 days (the legal limit in the UK, Israel, China and many other countries), which is of course still at a very early stage of the journey towards becoming a baby. But Jacob Hanna, who led the Israeli project at the Weizmann Institute of Science, told Technology Review that it sets the stage for other species I hope that it will allow scientists to grow human embryos until week five.

At the same time, advances in biology are enabling the creation of entirely new types of embryo-like structures, which some call simbryos, by assembling from scratch the embryonic cells of humans and other animals. Because these entities are in some sense artificial, though made from ordinary living cells, researchers arent sure if they qualify as genuine embryos, and so whether they should fall under the 14-day legal constraint. Meanwhile, scientists in the US and China have recently reported making chimeric embryos that contain a mixture of human and monkey cells, which they could keep alive in vitro for up to 20 days.

All these studies are motivated by biomedical questions and needs, from trying to understand the early stages of human development (and what can go wrong, for example, leading up to miscarriages) to trying to grow human organs for transplants within livestock animals. Yet they are also blurring boundaries: between natural and artificial, tissue culture and actual conception, humans and other species. We are, in the words of academic Susan Merrill Squier, replotting the humanand, so far, with no moral framework to guide us.

We havent even decided what the important questions are, let alone how to answer them

When the Warnock Committee, chaired by moral philosopher Mary Warnock, was established in 1982 to navigate the thicket opened up by IVF, it intentionally ducked the issue of the human embryos moral status. A key strategy of the Warnock Committee, says Sarah Franklin, director of the Reproductive Sociology Research Group at Cambridge, was to eschew the moral debate, for the simple reason it can never be resolved. The committees recommendation of the 14-day rule was pragmatic: this is roughly the point after which an embryo cannot split into twins, and so served as an otherwise entirely arbitrary kind of proxy for personhood. No more rigour was needed because there was not at that stage any practical possibility of going beyond that line.

But technological advances mean that governments and scientific bodies are reconsidering the 14-day ruleand thereby taking the lid back off the moral debate. Simbryos might simply sidestep itbut should they? These are dilemmas that science has created but cannot answer. The great danger is that, amid the murk, we will grab onto polarised ideologies in the hope of settling things.

Eugenic hatcheries

Arguments about embryology have long been divisive, and come weighted down with heavy cultural baggage. Growing embryos and even babies ex utero was christened ectogenesis in the early 20th century; its possibility motivated the biologist JBS Haldane to write Daedalus, or Science and the Future in 1924. Haldane presented a fictionalised future in which ectogenesis was introduced in the 1950s to combat plummeting birth rates. His narrator explains that, by 2073, less than a third of children were still born of woman.

Haldane welcomed this prospect. First, he said, it would allow population increase to be rationally planned and controlled. Better still, it would be possible to control who reproduced. Like many of his progressive contemporaries, while he supported female emancipation, he worried that better educated, well-bred women would prefer their new opportunities over their traditional role as mothers, leading to a decline in the quality of the gene pool. Ectogenesis could facilitate the necessary corrective of eugenic engineering. An enthusiasm for eugenics was shared by Haldanes friend Julian Huxley, who served as vice president and then president of the British Eugenics Society from 1937 to 1962. (No, eugenic advocacy was not killed off by the example of the Nazis.)

But Huxleys brother Aldous was less taken with Haldanes vision of a bioengineered population grown in artificial wombs. That scenario supplied the inspiration for the dystopian Brave New World (1932), with its hatcheries in which foetuses are chemically manipulated for intelligence to create the hierarchical society of the World State.

At one time, both men and women sympathetic to the feminist cause welcomed ectogenesis. In Hymen, or The Future of Marriage (1927), Norman Haire suggested that animals might instead act as gestational surrogates: human babies born to chimp mothers, for example. The pioneering feminist Vera Brittain, however, conceded in Halcyon, or the Future of Monogamy (1929) that natural methods of reproduction might make a comeback after a period of ectogenesis because children born outside the womb could suffer psychological problems. The trailblazing feminist writer Shulamith Firestone was another fan of ectogenesis. Her 1970 book The Dialectic of Sex portrayed childbearing as a primary cause of gender inequality: I submit, she wrote, that the first demand for any alternative system must be the freeing of women from the tyranny of their reproductive biology by every means available.

For all its humanitarian objectives, embryonic research remains ethically fraught

In stark contrast, more recent feminists have warned that artificial wombs could remove from women a source of social power. Australian sociologist Robyn Rowland worries: We [women] may find ourselves without a product of any kind with which to bargain if that last power is taken and controlled by men, what role is envisaged for women in the new world? Will women become obsolete? Another worry is expressed by bioethicist Rosemarie Tong, who fears a commodification of the whole process of pregnancy [and] a view of the growing child as a thing.

History shows, then, that while putative reproductive technologies like ectogenesis and artificial wombs have long been controversial, the terms of the debate have shifted with social perceptions and attitudes. We havent even decided what the important questions are, let alone how to answer them.

Towards artificial wombs

True ectogenesis is still a far cry from what the Israeli group has just achieved. Their mouse embryos do not really exist in an artificial womb as such; they float freely in a nutrient medium, including human blood serum taken from the umbilical cord, in rotating glass jars kept at a carefully controlled temperature and in levels of dissolved oxygen elevated above normal. Because they have no placenta to attach to or umbilical cord to supply blood, eventually they die through lack of oxygen.

The work is impressive, but growing small mammal embryos far into gestation in artificial cell-culture conditions is not completely new. For example, developmental biologist Lynne Selwood at the University of Melbourne has been able to culture embryos of the stripe-face dunnarta mouse-like marsupialto within a few hours of full term. (Their gestation period is 11 days, the shortest of any mammal, and marsupials are born premature relative to other mammals.) Selwoods interest in the technique was its potential use for conservation: breeding and preserving the species from frozen embryos, for example.

Only in the past few years have researchers, such as Magdalena Zernicka-Goetz at Cambridgeone of Prospects World Top 50 Thinkers last yearmanaged to grow human embryos in vitro right up to that 14-day limit. The difficulties, both practical and ethical, of investigating human embryos inside the womb mean that plenty remains unknown about their genetics, cell biology and tissue and organ formation. Ex utero studies beyond two weeks could potentially help us to understand and avoid, for example, miscarriages and growth defects that might cause disability or even death for babies carried to full term.

You neednt be a pro-lifer to accept there is still an urgent need to think all the consequences through

For all its humanitarian objectives, though, such research remains ethically fraught. A five-week-old human embryo, say, is very different from the shapeless mass of cells and folded tissues at 14 days: it has a shrimp-like form, with a rudimentary head, a neural tube that eventually becomes the central nervous system and brainas well as a beating heart. In other words, it is more recognisably human. (When the foetus can potentially feel pain is not clearthat has generally been deemed impossible before the brains cortex matures at around 24 weeks, but some argue that pain of a kind, if not an awareness of suffering, might be registered as early as 12 weeks.)

Of course, abortion of such embryos is permitted well into pregnancy in many countriesup to 24 weeks (and in exceptional cases later) in Great Britain. But technologies for gestation in artificial wombsboth for the early embryo as in the latest Israeli work, and life support for very premature babiescould seriously complicate the legal and ethical dilemmas. If these two methods, coming from opposite directions, meet in the middle so that the entire gestational period becomes technologically supportable, then genuine Huxlerian ectogenesis becomes an option. Women with potentially life-threatening pregnancies might then no longer be faced with termination as the only optionbut the law doesnt currently cover such a scenario. And how would abortion rights fare in the face of a putative technological solution that can preserve the life of the embryo or foetus? Its far from inconceivable that a state with strong anti-abortion leanings could mandate continued ex utero gestation rather than termination.

Such questions remain hypothetical: creating true artificial wombs is challenging, and the field has advanced at a snails pace for decades. But the latest work by Jacob Hanna and colleagues is a reminder of the direction of travel.

Sustaining human embryos beyond 14 days would not, however, currently be done with reproduction in mind. The aim is basic research for understanding developmental biology. An alternative approach for doing that, which would evade the 14-day rule, is to build synthetic embryo-like structures from stem cells. In the right conditions, you dont need to do much more than bring the right sorts of cells togetherthey will organise themselves spontaneously into a configuration more or less resembling an embryo. Two teams in the US and Australia have recently described the in vitro generation of human blastoidsstructures similar to early-stage embryosfrom stem cells either taken from actual embryos or reprogrammed from adult skin cells. These blastoids resemble the so-called blastocyst, the stage that a human embryo reaches around five to nine days after fertilisation, when it is ready to implant in the uterus wall. The blastoids contain not only the mass of stem cells that will become the foetus, but also the cell types that can develop into the tissues needed to sustain and contain it: the yolk sac and the placenta. The team in Texas showed that their blastoids could attach themselves to the culture dish to mimic uterine implantation, and then continue to develop.

Blastoids are just one example of what some have dubbed synthetic human entities with embryo-like features (SHEEFs); though simbryos is a catchier name. As they are not made by fertilisation of an egg by sperm, their legal and ethical status is unclear, and there is no consensus on regulation. UK and EU patent law rules that a synthetic cellular entity cant be considered a human embryo if in the light of current scientific knowledge, it does not, in itself, have the inherent capacity of developing into a human being. In the US an absence of federal laws might mean that the guidelines of the International Society for Stem Cell Research (ISSCR) are adopted. These were revised in May, and advise that such research be governed by case-by-case considerationbut that such entities should not be transferred to the uterus of either a human or another animal. Current simbryos almost certainly couldnt develop into a foetus in any casebut as they become ever better mimics of natural embryos, we cant be sure what potential they might have. Whether they could become babies is a crucial question, says bioethicist Hank Greely of Stanford University in California, but can we resolve that ethically? We wont know without trying it in humanswhich we cant do.

The edge of human

This science is in a Catch-22 situation, Greely says. We want to do research about humans that we cant ethically do on humans, so we go to non-human models. Existing non-human models [such as animals] arent that good, so we make new, better modelslike simbryos. But the dilemma is the better the models getthe more human they arethe more we get back into the same ethical issues. Biotechnologies like simbryos and chimeric embryos, suggest Greely and Bartha Maria Knoppers of McGill University in Montreal, are nibbling at the legal definition of what a human is.

The new ISSCR guidelines advise relaxation of the 14-day rule on human embryo research, to be replaced by a case-specific decision on what the limit should be. Changes to national legislation will be needed to enact this in many countries. But if that happens, some anticipate not only learning more about human embryo development but even harvesting nascent organs from such embryos, such as pancreases or kidneys, that might be grown further in vitro for transplantation. It might also be possible to use embryos grown for several weeks to test the safety of human gene editing, for example, to avoid some nasty genetic diseases.

History suggests that our response to disruptive technology will be highly dependent on contingent cultural preoccupations

Even with such potential medical benefits, you neednt be a pro-lifer to accept there is an urgent need to think all the consequences through. Our ability to transform, manipulate and culture cells takes us into uncharted territory where the boundaries of natural and artificial, and even of the human and non-human, are blurred. No off-the-shelf moral framework can be expected to guide the should and shouldnt. And history suggests that our response to disruptive technology will be highly dependent on contingent and perhaps ephemeral cultural preoccupations and prejudices. To track a responsible and humane path forward, we needsomehowto try and look beyond them.

Scientists lack the training and often the desire to take on that role. But the stifling of stem cell and embryo research in the US by George W Bushs 2001 Council on Bioethics shows what happens when religious conservatives are given the reins. As that panel showed, bioethics is a label that covers a multitude of sins and sometimes shows no inclination to examine its own assumptions. And heaven forbid that these issues be allowed to become fresh fuel for the culture wars. If we can reconstitute the collective and pragmatic wisdom of the Warnock Committee, it wont be a moment too soon.

The rest is here:
Replotting the human: the thorny ethics of growing babies outside the womb - Prospect

Crossroads of life: Jordan Reed’s journey through concussions, injuries and post-NFL healing – The Athletic

LEESBURG, Va. The 2020 season had just ended, and tight end Jordan Reed already was imagining an improved version of himself for 2021. Only 30 years old, the tight end dreamt of what could be his best year yet.

Then, while he was meditating one morning in his home in Palo Alto, Calif., it started.

Ringing in his ears.

He had heard it before, but it never lasted. This time, it wasnt going away.

Sometimes it was audible, sometimes just vibration. At times it was loud; other times soft. It could be a high-pitched squeal, almost like a dog whistle, or sound like a breeze through a tunnel. Sometimes it was a low-pitched buzz, as if it came from a speaker with a wiring problem.

The ringing was there when he was showering, pumping gas, throwing punches at his trainers mitts and watching his daughters soccer practice. It was worse when he tried to sleep.

Visit link:
Crossroads of life: Jordan Reed's journey through concussions, injuries and post-NFL healing - The Athletic

Human Embryonic Stem Cells Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 The Courier – The Courier

Latest research report, titled GlobalHuman Embryonic Stem Cells MarketInsights 2021 and Forecast 2026, This includes overview and deep study of factors which are considered to have greater influence over future course of the market such asmarket size, market share, different dynamics of the industry, Human Embryonic Stem CellsMarket companies, regional analysis of the domestic markets, value chain analysis, consumption, demand, key application areas and more.The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more.

Top Key players profiled in the report include:ESI BIO, Thermo Fisher, BioTime, MilliporeSigma, BD Biosciences, Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics, Cell Cure Neurosciences, PerkinElmer, Takara Bio, Cellular Dynamics International, Reliance Life Sciences, Research & Diagnostics Systems, SABiosciences, STEMCELL Technologies, Stemina Biomarker Discovery, Takara Bio, TATAA Biocenter, UK Stem Cell Bank, ViaCyte, Vitrolifeand More

To Get PDF Sample Copy of the Report(withcovid 19Impact Analysis):https://www.syndicatemarketresearch.com/sample/human-embryonic-stem-cells-market

Our Research Analyst implemented a Free PDF Sample Report copy as per your Research Requirement, also including impact analysisofCOVID-19 on Human Embryonic Stem CellsMarket Size

The COVID-19 Outbreak:Global Human Embryonic Stem CellsMarket study covers current status, % share, future patterns, development rate, SWOT examination, sales channels, to anticipate growth scenarios for years 2021-2026. It aims to recommend analysis of the market with regards to growth trends, prospects, and players contribution in the market development.

On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split into Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells

Market Segment by Applications, can be divided into: Research, Clinical Trials

Global Human Embryonic Stem CellsMarket by Geography:

Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe(Turkey, Germany, Russia UK, Italy, France, etc.) North America(the United States, Mexico, and Canada.) South America(Brazil etc.) The Middle East and Africa(GCC Countries and Egypt.)

Years Considered to Estimate the Market Size: History Year:2018-2021 Base Year:2021 Estimated Year:2021 Forecast Year:2021-2026

Get Upto $1000 Flat Discount on All License Type@https://www.syndicatemarketresearch.com/inquiry/human-embryonic-stem-cells-market

Reasons to buy:

Some Major TOC Points:

1.Human Embryonic Stem CellsMarket Overview 1.1 Introduction 1.2 Scope 1.3 Assumptions 1.4 Players Covered 1.5 Market Analysis By Type 1.5.1 Global Human Embryonic Stem CellsMarket Size Growth Rate By Type (2021-2026) 1.5.2 1.6 Market By Application 1.6.1 Global Human Embryonic Stem CellsMarket Share By Application (2021-2026) 1.6.2 Application 1

2. Executive Summary

3. Human Embryonic Stem CellsMarket Analysis By Type (Historic 2016-2021) 3.1 Global Human Embryonic Stem CellsMarket Size Analysis (USD Million) 2016-2021 3.1.1 Type 1 3.1.2 3.2 Global Human Embryonic Stem CellsMarket Share Analysis By Type (%) 2016-2021

4. Human Embryonic Stem CellsMarket Analysis By Application (Historic 2016-2021) 4.1 Global Nanoscale Smart Materials Market Size Analysis (USD Million) 2016-2021 4.1.1 Application 1 4.1.2 Application 2 4.1.3 Application 3 4.2 Global Human Embryonic Stem CellsMarket Share Analysis By Application (%) 2016-2021

5. Human Embryonic Stem CellsMarket Analysis By Regions (Historic 2016-2021) 5.1 Global Human Embryonic Stem CellsMarket Size Analysis (USD Million) 2016-2021 5.1.1 Human Embryonic Stem CellsMarket Share By Regions (2016-2021) 5.1.2 United States 5.1.3 Europe 5.1.4 China 5.1.5 Japan 5.1.6 India 5.1.7 Rest Of The World

6. Key Companies Analysis/Company Profile

Continued..

For More Information with including full TOC:https://www.syndicatemarketresearch.com/market-analysis/human-embryonic-stem-cells-market.html

Customization of the Report:Glob Market Reportsprovides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Contact Us:

Email ID:sales@syndicatemarketresearch.com

Read more:
Human Embryonic Stem Cells Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 The Courier - The Courier

Conversion of mouse embryonic fibroblasts into neural crest cells and functional corneal endothelia by defined small molecules – Science Advances

INTRODUCTION

Corneal disorders are the vital leading cause of blindness, with 12.7 million patients suffering from corneal blindness globally (1). Corneal transplantation, which replaces the damaged cornea with healthy donated corneal tissue, is the primary therapy. However, fewer than 1.5% of patients requiring corneal grafts can receive allotransplants due to a global shortage of donor corneas. Corneal endothelial keratoplasty has grown exponentially and is currently indicated for close to half of all corneal transplantations (2). The corneal endothelium, a monolayer of dedicated cells essential for maintaining the corneas transparency and useful visual function, is naturally nonrenewable in vivo but is lost with age or in various disease states. Therefore, the massive global demand for corneal endothelia allograft cannot be fulfilled at the current rate of cornea donation. Recently, success with surgical grafting of in vitro cultured corneal endothelial cells (CECs) provided a critical proof of principle for a strategy to develop CEC-based cell therapies (3). However, it remains challenging to obtain sufficient CECs from healthy donor tissues.

Direct lineage reprogramming facilitates the generation of functional cell types independent of the donor organ for applications in cell replacement therapy (4). Terminally differentiated cells can be converted to other cell types in vitro by the introduction of lineage-specific transcription factors (TFs), bypassing the pluripotent state (510). Similarly, these conversions can also be induced by the overexpression of specific TFs in vivo (1113). In addition, direct lineage reprogramming mediated by TFs has been used in disease modeling (14), implying its potential for practical applications. Recently, the small moleculebased conversion of fibroblasts to other functional cells represents an attractive reprogramming strategy and has attracted much interest because of its safety and efficiency (1518).

Developmentally, the corneal endothelia originate from neural crest cells (NCCs) (19, 20), which are a population of transient and multipotent cells giving rise to diverse differentiated cell types, including peripheral neurons, glia, melanocytes, and several types of ocular cells (21). During ocular development in vertebrates, NCCs delaminate from the roof plate upon closure of the neural tube and migrate into the eye, where they form the periocular mesenchyme; this tissue further differentiates into diverse cell lineages, including the corneal endothelium, stroma, trabecular meshwork, and others (20, 22, 23).

In this study, we developed a two-step lineage reprogramming strategy to generate chemically induced CECs (ciCECs) from fibroblasts using defined small molecules. We screened a new cocktail of small molecules that could efficiently convert mouse fibroblasts into chemically induced NCCs (ciNCCs) bypassing the pluripotent state. The ciNCCs exhibited typical NCC features and could be further differentiated into ciCECs using another combination of small molecules in vitro. Through lineage tracing in Wnt1-Cre/ROSAtdTomato and Fsp1-Cre/ROSA26tdTomato fibroblasts, we confirmed that the ciNCCs and ciCECs were converted from fibroblast cells. The ciCECs showed similar gene expression profiles and self-renewal capacity to those of primary CECs (pCECs). Transplantation of the ciCECs into an animal model reversed corneal opacity, yielding clear tissue. Our findings provide a new approach to the generation of neural crestlike cells and functional corneal endotheliallike cells, providing a different alternative cell source for regeneration of corneal endothelia and other tissues derived from neural crest.

To identify the chemicals sufficient for ciNCC generation from mouse fibroblasts, we used a lineage tracing strategy to monitor the conversion process and excluded any NCCs from the starting mouse embryonic fibroblasts (MEFs) (Fig. 1A and fig. S1A). Wnt1-Cre transgenic mice have been validated as a lineage-tracing reporter model for NCC development (24, 25). In Wnt1-Cre/ROSA26tdTomato mice, tdTomato protein was faithfully expressed in NCCs. MEFs were isolated from Wnt1-Cre/ROSA26tdTomato mice at embryonic day 13.5 (E13.5). Because the NCC population was marked with tdTomato, we performed fluorescence-activated cell sorting (FACS) to collect the tdTomato population to exclude any NCCs or progenitors (the purified cells are hereinafter referred to as Wnt1-tdTomato MEFs; fig. S1B). We confirmed that the Wnt1-tdTomato MEFs were also negative for other NCC markers, including Sox10, P75, Pax3, HNK1, and AP2 (fig. S1, C and D).

(A) Schematic diagram of the reprogramming of NCCs from MEFs. (B) Effects of individual chemicals on ciNCC generation. Data are means SD; n = 3 independent experiments. (C) Enhancement effects of individual chemicals on the generation of ciNCCs. Data are means SD; n = 3 independent experiments. (D) Schematic illustration of our strategy to convert MEFs into ciNCCs. (E) Generation of Wnt1+ ciNCCs from MEFs using a cocktail of small molecules. DMSO, dimethyl sulfoxide. (F) Quantification of Wnt1+ cells induced by candidate cocktails at day 12. Independent experiments, n = 3. (G) Morphological changes on distinct days during the induction process of ciNCCs. Scale bar, 50 m. (H) Percentages of Wnt1-tdTomato+ cells induced by candidate cocktails on distinct days. Independent experiments, n = 3.

To generate ciNCCs from mouse fibroblasts, we hypothesized that small molecules shown to target NCC lineagespecific signaling would facilitate NCC reprogramming. Therefore, we selected 16 small molecules as candidates based on (i) the epigenetic regulation and signaling modulation of NCC development (2629) and (ii) enhanced neural lineage reprogramming. The small molecules for NCC reprogramming were as follows: valproic acid (VPA), SB431542, RepSox, LDN193189 (LDN), CHIR99021, Y-27632, retinoic acid (RA), Forskolin, A8301, EPZ004777 (EPZ), RG108, 5-azacytidine (5-Aza), SMER28, AM580, Parnate, and BMP4 (table S1). For initial screening, the Wnt1-tdTomato MEFs were cultured in a 24-well plate and treated with small molecules. After testing various small-molecule conditions, we found that a combination of SB431542, CHIR99021, and Forskolin yields consistent tdTomato expression (0.53 0.03%) (Fig. 1B). SB431542 is an inhibitor of transforming growth factor (TGF-) signaling, which is important for NCC differentiation (3032). Similarly, CHIR99021 is an inhibitor of glycogen synthase kinase 3 (GSK3) signaling, which is involved in promoting NCC fate (31, 33, 34). Forskolin, a adenosine 3,5-monophosphate (cAMP) agonist, is crucial in early reprogramming for mesenchymal-to-epithelial transition (MET) (35). For subsequent screening and optimization, we used the combination of SB431542, CHIR99021, and Forskolin as induction basal condition. We found that VPA (a histone deacetylase inhibitor), EPZ004777 [Disruptor of telomeric silencing 1-like (DOPTiL) inhibitor], and 5-Aza (a DNA methylation inhibitor) further enhanced the induction of Wnt1-tdTomato+ cells (Fig. 1C). Therefore, we used a chemically defined medium combined with a cocktail of six small molecules (VPA, CHIR99021, SB431542, Forskolin, 5-Aza, and EPZ004777) (hereafter termed M6) to reprogram mouse fibroblasts into ciNCCs (Fig. 1D). Expression of Wnt1-tdTomato in individual cells was observed as early as day 3 with M6 medium treatment (Fig. 1E). The M6 reprogramming medium effectively induced Wnt1-tdTomato+ cells at 3.67 0.21% (Fig. 1F). On days 5 to 7, inducted Wnt1-tdTomato+ colonies were observed in the M6 reprogramming medium (Fig. 1G and fig. S1E). These Wnt1-tdTomato+ cells and colonies had molecular feature similar to those of primary NCCs (pNCCs). The Wnt1-tdTomato+ cell number increased notably in small colonies at approximately day 12 (Fig. 1H). Although the generation of Wnt1-tdTomato+ NCCs was only as efficient as the conversion of human fibroblasts using TFs (33), merely 2 to 5% of cells were positive for Wnt1-tdTomato in this study. The results were reproducible in different batches of MEFs (n = 8), and MEFs with different genetic backgrounds (C57BL/6, 129C57BL/6, and 129) could also be converted into ciNCCs via M6 conditions (fig. S2). Together, these results indicate that M6 can reprogram MEFs into ciNCCs. Furthermore, M6 could induce neonatal mouse tail-tip fibroblasts (TTFs) into ciNCCs, albeit at a lower reprogramming efficiency (fig. S3).

In the reprogramming process of ciNCCs, Wnt1-positive cells appeared as early as day 3. Small cell colonies emerged toward day 5. With the extension of induction time, the Wnt1-positive cells proliferated gradually.

To obtain the ciNCCs, we performed FACS to collect the Wnt1-tdTomato+ cells on days 12 to 16. Established ciNCCs were serially propagated in NCC expansion medium containing N2, B27, basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF). Morphologically, M6-induced cells at P3 maintained typical NCC features in monolayer culture (Fig. 2A). After passaging, the ciNCCs became morphologically homogeneous. To further characterize the M6-induced Wnt1-tdTomato+ cells, we sought to examine their gene expression. Our results showed the ciNCCs expressed multiple NCC markers, including P75, HNK1, AP2, and Nestin (Fig. 2B). Furthermore, we tested if the ciNCCs have differentiation potential toward peripheral neurons, Schwann cells, and others. For differentiation of ciNCCs, these cells were cultured in different lineage differentiation media. After cultured for 2 to 4 weeks, the differentiated cells were examined by assessing the expression of the markers by immunostaining. Notably, the ciNCCs could also give rise to cells expressing specific markers for neuron, including Tuj1 and Peripherin (Fig. 2C). For melanocyte differentiation, we observed melanocytes after 2 to 3 weeks of induction (Fig. 2C). Our results of immunostaining showed that the ciNCCs could differentiate to Schwann cells. The induced Schwann cells were GFAP+ and S100+ cells (Fig. 2D). Further differentiation of these ciNCCs in vitro gave rise to mesenchymal lineages, resulting in typical mesenchymal cell morphology. Our results showed that these ciNCC-derived mesenchymal cells could give rise into osteogenic, adipogenic, and chondrogenic cells (Fig. 2E). Collectively, these data indicated that our ciNCCs could be induced to differentiate toward peripheral nervous system lineages and mesenchymal lineages.

(A) Morphology of M6-induced ciNCCs. Scale bar, 400 m. (B) Immunostaining showing that MEF-derived ciNCCs express P75, Sox10, HNK1, AP2, and Nestin. Scale bar, 50 m. (C) Representative images of melanocytes and differentiated ciNCCs stained with peripheral neuron markers. Scale bars, 50 m. (D) Differentiation of ciNCCs into Schwann cells and melanocytes with marker expression. Scale bar, 50 m. (E) ciNCCs were differentiated into mesenchymal lineages and further into adipocytes, chondrocytes, and osteocytes. Scale bars, 100 m.

The mechanisms prompting the differentiation of NCCs to CECs remain unclear (36, 37). The niche surrounding NCCs, for example, lens epithelial cells (LECs), determines their ultimate fate during differentiation (38). To generate mouse CEC-like cells from ciNCCs, we sought small molecules based on their importance in CEC organogenesis and maintenance in vitro. SB431542 (an inhibitor of TGF- signaling) was capable of inducing CEC-like cells from human pluripotent stem cell (PSC) (39, 40). A previous study has reported that the Wnt signaling inhibitor Dkk2 promotes NCC differentiation into CECs (39). We selected the chemical inhibitor CKI-7 as a substitute, which has been shown to block Wnt signaling by inhibiting casein kinase I (41).

We decided to use the medium containing SB431542 and CKI-7 for CEC differentiation from ciNCCs (Fig. 3A). After 7 to 15 days of culture in this differentiation medium, a small population outside or inside the clusters displayed typical tight aggregates with homogeneous and polygonal morphology (Fig. 3B). We also observed that these colonies rapidly expanded, and the small clusters merged into larger ones by days 12 to 15 (Fig. 3B and movie S1). These CEC-like cells grew rapidly and had strong proliferation ability. The ciNCC-derived CEC-like cells formed a monolayer of hexagonal and pentagonal cells. To confirm that the CEC-like cells were derived from ciNCCs, we differentiated tdTomato+ ciNCCs with CEC differentiation medium containing 5 M SB431542 and 5 M CKI-7. These tdTomato+ ciNCCs could also be subsequently induced to differentiate toward polygonal cells (Fig. 3C). We next assessed CEC gene expression including Na+/K+-ATPase (Na+- and K+-dependent adenosine triphosphatase), AQP1, ZO-1, and N-cadherin by immunofluorescence staining. The results showed that these cells expressed CEC-specific markers (Fig. 3D). The TTF-derived ciNCCs also could be induced into CEC-like cells and expressed multiple CEC markers (fig. S3, A and C). In this study, we identified the function of the CEC-like cells by Dil-labeled acetylated low-density lipoprotein (Dil-Ac-LDL) uptake (Fig. 3E). Global gene expression analysis by RNA sequencing (RNA-seq) showed that the CEC-like cells shared a similar gene expression pattern to that of pCECs, but this pattern was distinct from that of the initial MEFs (Fig. 3F). The presence of tight junctions in the CEC-like cells was observed by transmission electron microscopy (TEM) (Fig. 3G). To further monitor the reprogramming process, we confirmed the expression of a panel of NCC and CEC markers at distinct times by using quantitative reverse transcription polymerase chain reaction (qRT-PCR). By day 12, robust expression of NCC genes was detected in cells, including Hnk1, P75, Sox10, Sox9, Pax3, and Ap2 (Fig. 4A). In addition, similar kinetics of gene activation for CEC genes, such as Slc4a1c, Col8a1, Na+/K+-ATPase, Aqp1, and N-cadherin, were also detected by qRT-PCR (Fig. 4B). The genes that are known to be enriched in pCECs were greatly up-regulated in ciCECs. To validate the transition process from fibroblast to CECs, we analyzed the transcriptome by using RNA-seq (Fig. 4C). The expression of CEC signature genes in ciCECs was substantially up-regulated, consistent with that of pCECs, whereas fibroblast signature genes were markedly down-regulated. Notably, a panel of NCC marker genes was initially up-regulated and subsequently down-regulated during the induction process (16, 18, 40, 42, 43). Principal components analysis revealed that M6-treated cells were distinct from the original MEFs, indicating that chemical reprogramming led to marked transcriptional changes (Fig. 4D). These results indicate that the CEC-like cells obtained CEC identity. Collectively, these data suggest that the combination of SB431542 and CKI-7 effectively promoted the generation of CECs within 10 to 15 days in the ciNCC culture. Those fibroblast-originated CEC-like cells are thereafter referred to as ciCECs.

(A) Schematic diagram for the chemical reprogramming of ciCECs from MEFs. (B) Bright-field images of initial MEFs, reprogrammed ciNCC colonies, and ciCECs. Scale bar, 400 m. (C) Morphological changes on different days during the induction process of ciCECs from Wnt1-tdTomato+ ciNCCs. Scale bar, 400 m. (D) Immunofluorescence staining of ciCECs for the corneal endothelium markers Na+/K+-ATPase, AQP1, vimentin, N-cadherin, laminin, and ZO-1. Scale bars, 50 m. (E) LDL uptake function in ciCECs at P2 and pCECs at P3. Scale bar, 50 m. (F) Heatmap of differentially expressed genes among the samples at the indicated time points. These numbers below the heatmap indicate independent biological replicates. Red and blue indicate up-regulated and down-regulated genes, respectively. (G) TEM of ciCECs showing the tight junctions. Scale bar, 5 m.

(A) qRT-PCR analysis showing the expression of NCC genes at the indicated time points. Gene expression (log2) was normalized to that in MEFs. (B) qRT-PCR analysis of the expression of the indicated CEC genes in MEF-derived ciCECs at different passages, MEFs, and pCECs. (C) Heatmap of differentially expressed genes among samples at the indicated time points. The number below the heatmap indicates independent biological replicates (n = 12). Red and blue indicate up-regulated and down-regulated genes, respectively. (D) Principal components analysis of samples from day 0 (D0), day 7 (D7), and day 12 (D12) of reprogramming, ciCECs, and the control pCECs.

To confirm the origin of the initial fibroblasts for the small moleculebased reprogramming, we sought a genetic lineage-tracing strategy to purify fibroblast-specific protein 1 (Fsp1)tdTomato+ fibroblasts (Fig. 5A). Fsp1-Cre has been validated as a specific fibroblast marker for lineage tracing (44); thus, Fsp1-Cre mice were crossed with ROSA26tdTomato mice. MEFs were isolated from transgenic mice (Fsp1-Cre/ROSA26tdTomato) at E13.5, and the fibroblasts expressed tdTomato specifically; these cells are hereafter named tdMEFs (fig. S4A). To avoid possible contamination of the MEFs with NCC progenitor cells, we carried out FACS to collect the tdTomato+/p75 population (Fig. 5B and fig. S5G). These tdMEFs were negative for all NCC markers, including P75, HNK1, Sox10, and AP2 (Fig. 5C).

(A) Schematic diagram illustrating the genetic lineage-tracing strategy. MEFs were obtained by sorting for p75/tdTomato+ cells from MEFs derived from E13.5 mouse embryos of the Fsp1-Cre/ROSA26tdTomato background. (B) FACS result showing the p75/tdTomato+ cells from MEFs with a genetic background of Fsp1-Cre/ROSA26 tdTomato. (C) Immunostaining analysis showing negative results for Sox10, P75, HNK1, AP2, Sox2, and Pax6 in the p75/tdTomato+ cells. Scale bar, 100 m. (D) p75/tdTomato+ cell differentiation toward ciNCCs and ciCECs. Scale bars, 400 m. (E) Immunostaining analysis showing positive results for ZO-1, laminin, Na+/K+-ATPase, and AQP1 in the Fsp1-tdTomato-MEFderived ciCECs. Scale bar, 50 m.

Then, these tdMEFs were induced with the abovementioned M6 medium. Epithelial clusters expressing tdTomato were observed during ciNCC induction (Fig. 5D and fig. S4B). We passaged the Fsp1-tdTomato+ ciNCCs and cultured them in NCC expansion medium for further experiments (after 2 weeks of induction). Immunofluorescence analysis confirmed that these Fsp1-tdTomato+ ciNCCs were positive for the NC markers P75, HNK1, Sox10, and AP2, indicating that the colonies of Fsp1-tdTomato+ ciNCCs had the differentiation potential toward CEC-like cells (fig. S4C). Furthermore, the Fsp1-tdTomato+ ciNCCs could differentiate into tdTomato+ ciCECs (fig. S4D). By immunostaining, we found that differentiated CEC-like cells coexpressed Na+/K+-ATPase, AQP1, laminin, ZO-1, Na+/K+-ATPase, and tdTomato (Fig. 5E). Notably, all these ciCECs also expressed tdTomato, demonstrating a conversion from fibroblasts. The results confirmed that the ciNCCs and ciCECs were converted by two-step lineage reprogramming from fibroblasts.

Because the mechanism of our lineage reprogramming might be similar to that of chemically reprogrammed induced PSCs (iPSCs) (9, 16), we sought to assess whether the ciCECs went through an iPSC stage. We performed a comparison between chemical iPSC reprogramming and ciCEC induction from MEFs derived from mice harboring an Oct4 promoterdriven green fluorescent protein (GFP) (OG2) reporter (35, 45). The M6-treated MEFs morphologically underwent a characteristic MET, and small cell colonies gradually emerged toward day 6 (fig. S5A). These cell colonies expressed the NCC marker Sox10 (fig. S5B). In contrast, we did not observe any Oct4-GFPpositive cells during the entire process from MEFs to ciCECs based on our method (fig. S5, C and D). Furthermore, the ciCECs maintained a normal karyotype during 10 continuous passages in vitro (fig. S5E). To evaluate the potential risk of tumorigenesis, a total of 5 106 ciCECs and 2 106 mouse embryonic stem cells (mESCs) were transplanted subcutaneously into nonobese diabetic mice (NOD)/severe combined immunodeficient (SCID) mice. Notably, no tumors formed over 6 months after transplantation with ciCECs, whereas large teratomas developed in the mice transplanted with mESCs after 4 to 8 weeks (fig. S5F). This result suggests that the ciCECs have no tumorigenic potential. To better understand their differentiation in vivo, we transplanted ciCECs into the anterior chambers of the eyes of NOD/SCID mice. After 4 to 8 weeks, the transplanted ciCECs did not form tumors over 6 months after transplantation. These results demonstrated that our approach could directly reprogram MEFs to ciNCCs and eventually ciCECs while bypassing the iPSC stage.

The maintenance of cultured CECs with morphology and normal physiological function in vitro has proven challenging (46). We aimed to test whether large numbers of functional ciCECs could be generated from fibroblasts to enable the large-scale application of ciCECs. On the basis of our observations that ciCECs cultured in medium with SB431542 (5 M) and CKI-7 (5 M) were small, polygonally shaped cells (fig. S6A), we hypothesized that SB431542 and CKI-7 would promote ciCEC growth in vitro. We evaluated the long-term expansion capacity of ciCECs in vitro by continuously passaging ciCECs at a 1:6 ratio and found that the phenotype was similar between P3 and P30 (Fig. 6, A and B). This result showed that SB431542 and CKI-7 strongly promoted ciCEC expansion. These ciCECs sustained themselves as a homogeneous cell population for at least 30 passages (P30) with hexagonal morphology in small moleculebased medium. In addition, we successfully clonogenically cultured these ciCECs to 10 passages and demonstrated consistent morphologies. Our results of immunostaining showed that the rate of Ki67-positive cells was higher in ciCECs at P3 than in pCECs at P3 (fig. S6B). ciCECs were highly proliferative, as 24.6, 37.8, and 48.1% of these cells showed incorporation of ethynyl deoxyuridine (EdU) at P1, P3, and P6 (fig. S6C). The results of FACS analysis with propidium iodide (PI) staining showed that the cell cycle distribution (G0-G1, S, and G2-M phases) was 46.30, 45.11, and 8.59% for ciCECs at P3 and 67.30, 21.50, and 11.20% for pCECs at P3 (fig. S6D). They rapidly expanded into large, homogeneous colonies with population doubling times of 22.3 3.7 hours (Fig. 6C). Large vacuole-like structures were found on the surface of the ciCECs at P2 to P10 (Fig. 6D). These vacuole-like structures disappeared at P20 when they were serially propagated. Notably, the ciCECs at P30 also expressed typical CEC markers, including Na+/K+-ATPase, AQP1, and ZO-1 (Fig. 6E). When assayed by imaging for the ability to migrate into the space created by a scratch wound, ciCECs cultured in medium with SB431542 and CKI-7 at different passages showed a stronger capability of proliferation and migration as compared to that of pCECs (fig. S6, E and F). Collectively, these results demonstrated that SB431542 and CKI-7 had a robust and general effect on long-term expansion of ciCECs in vitro.

(A) ciCECs were expanded for 3 days in serum-free control medium. Scale bar, 200 m. (B) Serial expansion of ciCECs in the serum-free medium with addition of SB431542 and CKI-7. Scale bar, 200 m. (C) Average population doubling times (means SD, n = 3; ***P < 0.001) of the ciCECs cultured in medium with and without SB431542 and CKI-7. (D) Bright-field image of ciCECs at P5, which were expanded for 3 days in culture condition with addition of SB431542 and CKI-7. Arrows indicate the vacuole-like structures. Scale bar, 50 m. (E) These ciCECs at P30 were fixed and stained for Na+/K+-ATPase, AQP1, and ZO-1. Scale bar, 50 m.

To evaluate whether the ciCECs had the capacity to regenerate the corneal endothelia in vivo, we transplanted them into a well-established rabbit model with bullous keratopathy by mechanically scraping corneal endothelia from Descemets membrane (47, 48). A previous study found that injection of human pCECs supplemented with a ROCK inhibitor restored endothelial function (49). Corneal edema decreased much earlier after ciCEC transplantation in the grafted eyes than in the untreated eyes. Compared to the untreated eyes, which showed that the clarity of the cornea was unchanged, we noted that the clarity of the cornea of the grafted eyes increased gradually after transplantation (Fig. 7A). After 7 days, the corneas of the grafted eyes became transparent, while corneal opacity and stromal oedema remained poor in the untreated eyes. The results of slit-lamp examination showed that the clarity of the cornea of the grafted eyes was also notably improved after injection, and the pupil and iris texture could be clearly observed (Fig. 7B and fig. S7A).

(A) Diagram depicting the transplantation of ciCECs with the ROCK inhibitor into model rabbits. (B) Corneal transparency in the grafted eyes was notably improved after transplantation, while corneal opacity and stromal oedema were still serious in the untreated controls. (C) Slit-lamp microscopic images showing that the clarity of the grafted corneas was substantially improved after transplantation, while corneal opacity and stromal oedema remained in the untreated controls. (D) Immunohistochemistry showing that surviving tdTomato+ ciCECs were attached to Descemets membrane. Scale bar, 100 m. (E) Visante OCT showing ameliorated corneal oedema (reduced corneal thickness) in a grafted eye. (F and G) Trend in corneal thickness and corneal clarity after transplantation. There were significant differences in corneal thickness and transparency between the untreated controls and the grafted groups. The results are means and SEM for biological replicates (n = 9). (H) Live confocal imaging of corneal endothelia confirmed full coverage of polygonal cells on Descemets membrane in the grafted eyes. Photo credit: Zi-Bing Jin, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Science Key Laboratory, Beijing, 100730 China.

Next, we investigated ciCEC survival in the grafted eyes. Eyeballs were enucleated at postsurgical day 28 to evaluate the transplanted ciCECs. Fluorescence microscopy examination confirmed the existence of tdTomato-tagged grafted cells. Visante optical coherence tomography (OCT) of the anterior segment also showed that the corneal thickness decreased after ciCEC injection (Fig. 7C and fig. S7C). Confocal microscopy confirmed full coverage of polygonal endothelial cells on Descemets membrane in the ciCEC-grafted disease models, while this could not be detected in the untreated models due to their severe corneal opacity (Fig. 7D). Under magnification, the grafted ciCECs tightly adhered to the posterior surface of the cornea in a monolayer, whereas the Descemets membranes in the untreated model were bare and had no detectable CECs on day 28. Immunohistochemistry demonstrated ZO-1 expression, indicating the adhesion of injected cells onto the corneal tissue (Fig. 7E and fig. S7D).

There was a rapid decrease in corneal thickness within 4 weeks after ciCEC injection, followed by a more gradual decrease over the next 2 weeks (Fig. 7F and fig. S7E). In the untreated group, mean corneal thickness was approximately 1200 m throughout the 42 days of observation. In contrast, it decreased rapidly in the grafted group, being significantly less than that in the untreated group. We observed that the mean corneal thickness at postoperative days 14 (P < 0.01), 21, 28, 35, and 42 (P < 0.001) in the ciCEC-grafted group was significantly less than that in the control group, indicating that corneal edema was markedly reversed. Meanwhile, corneal clarity gradually increased after ciCEC transplantation, and grafted corneas had higher corneal transparency compared to untreated controls (Fig. 7G). These results strongly suggest that ciCEC transplantation repopulated and self-organized on the posterior surface of the cornea and has the capacity to regenerate the corneal endothelium. In this study, the ciCECs were injected combined with a ROCK inhibitor (Y-27632) into the anterior chambers of the eyes (Fig. 7H and movie S2). Each recipient received 1 106 ciCECs. Fellow eyes (normal) and untreated eyes [phosphate-buffered saline (PBS) injection] were used as experimental controls.

Previous studies have reported that NCCs can generate from fibroblasts by introducing NCC-specific TFs (33, 42). In this study, we demonstrated that ciNCCs could be generated from MEFs via a small-molecule reprogramming method in vitro. The generated ciNCCs resemble NCCs in the expression profile of signature genes, capacity for self-renewal, and the differentiation potential into derivative neurons, Schwann cells, and mesenchymal lineages. These finding demonstrated that direct lineage-specific conversion to NCCs from MEFs could be achieved by the manipulation of signaling pathways with small molecules. In addition, given the broad spectrum of NCC derivatives, our approach for developing ciNCCs holds great potential as a different source to generate other NCC-derivative cell types (50).

Furthermore, we successfully generated functional ciCECs from ciNCCs. We explored defined differentiation conditions including SB431542 and CKI-7 to achieve this process in vitro. ciCECs showed an expression profile and function close to those of mature CEC. These ciCECs were found to expand further and maintain contact-inhibited hexagonal phenotype in the defined serum-free chemical medium. The maintenance of pCECs in vitro has been proven challenging. When grown under normal culture conditions in vitro, pCECs often show morphological fibroblastic changes and lose their physiological function (43, 51). A TGF- inhibitor maintains the CEC phenotype during the process of ciCEC generation. A previous study showed that SB431542 assisted in the maintenance of cultivated CECs with a normal polygonal and functional phenotype (52). We found that the ciCECs could maintain normal polygonal morphology and function in the medium with SB431542 and CKI-7 over the long term. Notably, these cells could be serially expanded up to 30 passages and maintained contact-inhibited hexagonal phenotype. The contact-inhibited plays important roles in keeping the monolayer structure of ciCECs. Thus, it does not allow ciCECs to overproliferate in vitro and in vivo. During the passage, main genes related to maturation were increased, indicating that they were mature ciCECs.

Corneal endothelium is derived from periocular NCCs (53). Previous reports have shown that PSCs can differentiate into CECs with a conditioned medium (36, 37, 39). Defined medium containing small molecules promoted PSC to differentiate into CEC-like cells (39). Most approaches for the generation of CECs from stem cells in vitro were stepwise procedures according to the developmental process. Consistent with previous studies, the lineage conversion from mouse fibroblasts is also a stepwise procedure. The induction strategy for ciCECs is composed of two major steps, including an initial chemical conversion of ciNCCs from mouse fibroblasts, followed by lineage-specific differentiation into ciCECs. The ciCECs have advantages over the PSC-derived CECs in certain aspects. The small moleculebased conversion from fibroblasts makes the generation of ciCECs safe, which have no tumorigenic potential. Moreover, ciCECs can be produced from individual patients, thus developing individualized cell therapy (40).

The generation of large numbers of functional CECs for cell-based approaches to corneal endothelial dysfunction is an important goal. Direct reprogramming of fibroblasts to CECs could offer a solution to this problem. The ciCECs exhibited a monolayer of hexagonal shaped cells in vitro. In vivo engraftment of ciCECs substantially reversed the corneal opacity in the rabbit corneal endothelial dysfunction model, indicating their therapeutic effect for corneal endothelial deficiency. A previous study has shown that cultivated rabbit CECs injected with Y-27632 were successful in recovering complete transparency of the corneas (47). However, further commenting is needed on the immunologic rejection of xenotransplantation that occurs in this study.

It has been known that MEFs contain a heterogeneous population of nonfibroblast precursor cells (16). To avoid possible contamination of NCCs in the starting MEFs, we carried out a lineage-tracing experiment to track the origin of the ciNCCs and ciCECs. We verified that the Wnt1+ ciNCCs were generated from non-NCC fibroblasts. To further confirm the origin of the ciNCCs, we confirmed that the tdTomato-positive ciNCCs generated from fibroblasts and engrafted Fsp1-tdTomato ciCECs in the animal model by using a fibroblast-specific Fsp1-Cre lineage-tracing reporter in MEFs.

In conclusion, our study presents a new strategy to generate functional CECs through induction of NCCs with chemically defined small-molecule cocktails, providing a new source of neural crest derivatives for the purpose of corneal engineering and regeneration.

The Wnt1-Cre [Tg(Wnt1-Cre)11Rth], Fsp1-Cre [BALB/c-Tg (S100a4-cre)1Egn/YunkJ], and ROSA26-tdTomato [Gt(ROSA)26Sortm14(CAG-tdTomato)Hze] mice were obtained from The Jackson Laboratory; the Oct4-GFP transgenic allelecarrying mice (CBA/CaJC57BL/6J) were also obtained from The Jackson Laboratory; and the 129Sv/Jae and C57BL/6 mice were obtained from Shanghai Vital River Laboratory. The rabbits used in this study were of the New Zealand white strain and were obtained from JOINN Laboratories (Suzhou) Inc., Suzhou, China. All the animals were housed under stable conditions (21 2C) with a 12-hour dark/light cycle. All animal experiments were approved by the Animal Ethics Committee of Wenzhou Medical University, Wenzhou, China.

MEFs were isolated from E13.5 embryos as previously described (54). Briefly, the neural tissues (including head, spinal cord, and tail), limbs, gonads, and visceral tissues of the E13.5 mouse embryos were carefully removed and discarded before MEF isolation. The remaining tissues were sliced into small pieces, trypsinized, and plated onto 10-cm dishes in fibroblast medium. Mouse NCCs were isolated from the neural tube of E8.5 embryos under a dissection microscope as previously described (55). The mouse meninges and vessels were removed and discarded. The remaining brain tissues were sliced into small pieces, dissociated with 0.25% trypsin (Gibco) for 15 min at 37C, washed with Dulbeccos modified Eagles medium (DMEM)/F12 twice, and then plated in a T25 flask bottle in NCC medium, which is composed of DMEM/F12 (Gibco) supplemented with 1 N2 (Gibco), 1 B27 (Gibco), bFGF (20 ng/ml) (PeproTech), and EGF (10 ng/ml) (PeproTech). Mouse pCECs were isolated from postnatal day 30 (P1)2 pups following a published protocol (56). They were cultured in DMEM containing 10% fetal bovine serum (FBS) (Gibco), 0.1 mM nonessential amino acids (NEAAs) (Sigma-Aldrich), 2 mM GlutaMAX (Gibco), and 2 mM penicillin-streptomycin (Gibco). The mESCs were maintained in ESC medium, which is composed of DMEM with 1 N2 (Gibco), 1 B27 (Gibco), leukemia inhibitory factor (LIF), 0.1 mM nonessential amino acids (Sigma-Aldrich), 2 mM GlutaMAX (Gibco), 2 mM penicillin-streptomycin (Gibco), 0.1 mM 2-mercaptoethanol (Gibco), CHIR99021 (3 mM), and PD0325901 (1 mM).

Primary MEFs were isolated from E13.5 mouse embryos with a genetic background of Wnt1-Cre/ROSA26tdTomato (Wnt1-Cre mice ROSA26tdTomato mice) and Fsp1-Cre/ROSA26tdTomato (Fsp1-Cre mice ROSA26tdTomato mice). The MEFs at P2 were dissociated with 0.25% trypsin at 37C for 5 min and neutralized with MEF medium. To prepare the Fsp1-MEFs, the resulting fibroblasts were sorted to obtain tdTomato+/p75 cells by FACS. These MEFs were stained with a specific antibody against p75 and subjected to FACS for tdTomato+/p75 cells. During FACS, a Matrigel-coated 24-well plate was prewarmed at 37C for at least 30 min before seeding the tdMEFs. The tdMEFs were planted immediately after FACS into the prewarmed Matrigel-coated 24-well plate at 1.5 104 cells per well in MEF medium in 5% CO2 and 20% O2 at 37C for 5 hours to allow the cells to attach to the plate.

Small molecules, including the GSK3 inhibitor CHIR99021, the TGF- inhibitor SB431542, the cAMP inducer Forskolin, and CKI-7, were acquired from Sigma-Aldrich. bFGF was acquired from PeproTech. All chemical components are described in table S1.

M6 reprogramming medium preparation. The basal medium contained knockout DMEM (Gibco), 10% KSR (KnockOut serum replacement) (Gibco), 10% FBS (Gibco), 1% NEAA (Gibco), and 0.1 mM 2-mercaptoethanol (Gibco) supplemented with the small molecules CHIR99021 (3 M), SB431542 (5 M), Forskolin (10 M), VPA (500 mM), EPZ004777 (5 M), and 5-Aza (0.5 M). The medium was shaken for 30 min to ensure that all components were fully dissolved.

CEC differentiation and medium preparation. DMEM/F12/GlutaMAX (Gibco), 10% KSR (Gibco), 1% NEAA (Gibco), and 0.1 mM 2-mercaptoethanol (Gibco) were supplemented with SB431542 (5 M) and CKI-7 (5 M).

Chemical conversion of NCCs from mouse fibroblasts. The MEFs and TTFs were plated at 5 104 cells per well on six-well tissue culture plates in fibroblast medium. The culture plates were precoated with fibronectin or laminin for more than 2 hours. After overnight culture, the medium was exchanged with M6 chemical medium, which was refreshed every 2 days. NCC-like cells appeared and increased at days 3 to 5. After 7 to 10 days of induction, FACS was performed to collect Wnt1+ cells.

Generation of ciCECs from mouse ciNCCs. On days 12 to 16, the M6 chemical medium was replaced with CEC differentiation medium, which was refreshed every 2 days. Endothelial-like cell clusters appeared as early as day 20. During days 30 to 35, these CEC-like cell colonies were counted or further detected.

Cells were washed once with 1 PBS and then fixed with 4% paraformaldehyde at room temperature for 10 to 15 min, followed by permeabilization with 0.2% Triton X-100 in 1 PBS for 10 min and blocking with 7.5% bovine serum albumin (BSA) for at least 1 hour. All primary antibodies were diluted in 7.5% BSA, and the primary antibody reactions were incubated at 4C overnight. Then, the cells were washed with 1 PBS for 10 min five times at room temperature. The secondary antibodies with Alexa Fluor 488, Alexa Fluor 555, and Alexa Fluor 647, purchased from Invitrogen, were diluted in 7.5% BSA, and incubation was performed for 1 hour at room temperature, followed by five 10-min washes with 1 PBS. The nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). The antibodies used in this study are listed in table S2.

Total RNA was extracted using an RNeasy Plus Mini kit (Qiagen). In brief, 1 g of total RNA was used for reverse transcription with an iScript cDNA synthesis kit (Bio-Rad), and the resulting complementary DNA (cDNA) was diluted five times in H2O for PCR. For semiquantitative PCR, 1 l of one-fifth diluted cDNA was used as template for the following PCR program: 95C for 5 min and 35 cycles of 95C for 30 s, 60C for 30 s, and 72C for 30 s, followed by 72C for 10 min. Quantitative PCR was performed following the FAST SYBR Green Master Mix (ABI) protocol. All PCR was performed in triplicate, and the expression of individual genes was normalized to that of Gapdh. The primer sequences are listed in table S3.

Total RNA for each sample was isolated with TRIzol reagent and purified using the RNeasy 23 Mini Kit (Qiagen) according to the manufacturers instructions. RNA quality and quantity were assessed using NanoDrop 2000, Agilent 2100 Bioanalyzer, and Agilent RNA 6000 Nano Kit. RNA library construction and RNA-seq were performed by the Annoroad Gene Technology. Sequencing libraries were generated using the NEB Next Ultra RNA Library Prep Kit for Illumina24 (NEB), and library clustering was performed using HiSeq PE Cluster Kit v4-cBot-HS (Illumina) following the manufacturers recommendations. After cluster generation, the libraries were sequenced on an Illumina platform and 150base pair paired-end reads were generated. The initial data analysis was performed on BMKCloud (www.biocloud.net/).

For MEF preparation, fibroblasts with the desired genotype were cultured in MEF medium until they reached more than 80% confluence. The cells were washed twice with 1 PBS and treated with 0.25% trypsin at 37C for 5 min. After harvesting, the cells were passed through a 70-m filter, washed twice with PBS, and resuspended in precooled buffer (1 PBS, 1.5% FBS, and 0.5% BSA). The cells were incubated with either fluorescein isothiocyanate (FITC)conjugated P75 antibody (Abcam) or isotype control (BD) at the suggested concentrations on ice for 30 min or room temperature for 45 min, followed by six washes with FACS buffer. Cells were then resuspended in FACS buffer and sorted with BD FACSAria II.

Approximately 5 103 ciNCCs were seeded on laminin-coated 24-well tissue culture plates and cultured in N2B27 medium, which contained 1 N2, 1 B27, EGF (10 ng/ml), and bFGF (10 ng/ml) in Neurobasal medium. After 24 hours, cells were subjected to differentiation conditions.

For peripheral neuron differentiation, the medium was switched to neuron differentiation medium [NCC medium without bFGF and EGF, with the addition of 200 M ascorbic acid, 2 M dibutyryl cAMP (db-cAMP), brain-derived neurotrophic factor (BDNF) (25 ng/ml), NT3 (25 ng/ml), and glial cell linederived neurotrophic factor (GDNF) (50 ng/ml)]. Half of the medium was changed every 2 to 3 days. Specific neuron markers were analyzed by day 10 to day 20 after differentiation.

For Schwann cell differentiation, ciNCCs were cultured in N2B27 medium for at least 2 weeks. Differentiation was then induced by culturing in NCC medium without FGF2 and EGF and supplemented with ciliary neurotrophic factor (10 ng/ml), neuregulin (20 ng/ml), and 0.5 mM db-cAMP for 3 to 4 weeks. Media were changed every 2 to 3 days. Cells were then examined for the expression of Schwann cell protein markers by immunostaining.

To differentiate into melanocytes, ciNCCs were cultured in the presence of 5 M RA and Shh (Sonic hedgehog) (200 ng/ml) for 1 day and platelet-derived growth factorAA (PDGF-AA) (20 ng/ml), bFGF (20 ng/ml), and Shh (200 ng/ml) for 3 to 5 days; then, they were cultured in differentiation medium containing T3 (40 ng/ml), Shh (200 ng/ml), 1 nM LDN193189, 5 mM db-cAMP, and NT3 (10 ng/ml) for 8 to 12 days. The medium was refreshed every other day.

For mesenchymal differentiation, ciNCCs were cultured for 3 weeks in -MEM containing 10% FBS, as previously described (57). The differentiation potential of ciNCC-derived mesenchymal stem cells was achieved by incubation with adipogenesis medium, osteogenesis medium, and chondrogenesis medium, respectively (Cyagen Biosciences). The differentiation medium was refreshed every 3 days. The induced cells were stained with Oil Red O stain kit (Solarbio), alizarin red S (Sigma-Aldrich), and Alcian blue (Sigma-Aldrich) after 3 weeks of induction.

Cells were carefully dissociated into single-cell suspensions by trypsin (Gibco), washed twice with PBS, and then fixed overnight with cold 70% ethanol. Fixed cells were washed twice with PBS, followed by ribonuclease (100 g/ml; Sigma-Aldrich) treatment and PI (50 g/ml; Sigma-Aldrich) staining for 30 min at 37C. Approximately 1 106 cells were analyzed using FACSCanto II (Becton Dickinson) to determine the cell cycle distribution pattern. The percentages of cells in the G1, S, and G2-M phases of the cell cycle were analyzed using ModFit 4.1 (Verity Software House).

For generation of teratoma in vivo, 5 106 ciCECs were subcutaneously injected into each recipient NOD/SCID mouse (n = 5). Control NOD/SCID mice (n = 3) were injected with 2 106 mESCs, and teratoma formed from 4 to 8 weeks. Then, images of mice were captured with the cell phone imaging system.

All rabbits weighing 2.0 to 2.5 kg were anesthetized intramuscularly with ketamine hydrochloride (60 mg/kg) and xylazine (10 mg/kg; Bayer). The rabbits were divided into two groups (n = 10 each group), and the right eye was used for this experiment. After disinfection and sterile draping of the operation site, a 6-mm corneal incision centered at 12 oclock was made with a slit knife, and a viscoelastic agent (Healon; Amersham Pharmacia Biotech AB) was infused into the anterior chamber. After the corneal surface had been ruled with a marking pen (Devon Industries Inc.), a 6.0-mm-diameter circular aperture for descemetorhexis was created in the center of the cornea with a 30-gauge needle (Terumo), and Descemets membrane was removed from the anterior chamber of the eye. The corneal endothelium was mechanically scraped from Descemets membrane with a lacrimal passage irrigator (Shandong Weigao) as previously described. Fsp-ciCECs were dissociated using 0.25% trypsin-EDTA, resuspended in basic medium at a density of 1 107 cells/ml, and kept on ice. The anterior chamber was washed with PBS three times. After this procedure, a 26-gauge needle was used to inject 1 106 cultured ciCECs suspended in 100 l of basic DMEM containing 10 M ROCK inhibitor Y-27632 (Selleck) into the anterior chamber of the right eye. Thereafter, rabbits in the ciCEC transplantation groups were kept in the eye-down position for 24 hours under deep anesthesia so the cells could become attached by gravitation. Each surgical eye was checked two or three times a week by external examination, and photographs were taken on days 3, 7, 14, and 28 after injection. Central corneal thickness was measured using the Spectralis BluePeak OCT unit (Heidelberg Engineering, Heidelberg, Germany), and CECs were imaged with confocal scanning laser ophthalmoscopy (HRT3, Heidelberg Engineering, Heidelberg, Germany) on days 0.5, 1, 3, 7, 14, 21, 28, 35, and 42 after surgery. An average of three readings was taken. Corneal transparency was scored using a scale of 0 to 4 as previously described (58), where 0 = completely clear; 1 = slightly hazy, iris and pupils easily visible; 2 = slightly opaque, iris and pupils still detectable; 3 = opaque, pupils hardly detectable; and 4 = completely opaque with no view of the pupils. Photographs of ocular surface were taken with slit-lamp microscopy (SLM-8E, KANGHUA, China) at each time point.

The proliferation rate of ciCECs cultured in differentiation medium was determined by the Click-iT EdU Alexa Fluor 488 Imaging Kit (Invitrogen) according to the manufacturers instructions. Briefly, passaged CECs were seeded onto a slide at a lower density of 5 103 cells per cm2 and cultured for 24 hours.

For TEM analysis, cells were fixed in 2.5% EM-grade glutaraldehyde (Servicebio) for 2 to 4 hours at 4C, washed with 0.1 M phosphate buffer (pH 7.4), postfixed in 1% osmium tetroxide for 2 to 4 hours at 4C, and washed and then dehydrated in an ethanol series (50 to 100%) to a final rinse in 100% acetone, followed by 2-hour incubations in 1:1 acetone/Pon 812 (SPI) and overnight incubation in 1:2 acetone/Pon 812. The samples were embedded in Pon 812, polymerized for 48 hours at 60C, and then sectioned (60 to 80 nm) with a diamond knife (Daitome). Sections were stained with 2% uranyl acetate, followed by lead citrate, and visualized using an HT7700 transmission electron microscope (HITACHI).

ciCECs and pCECs were cultured for 24 hours and then incubated with Dil-Ac-LDL (10 g/ml) (Invitrogen) in culture medium at 37C for 6 hours. Cells were washed three times with PBS and stained with FITC-lectin (10 mg/ml) (Sigma-Aldrich) at 37C in the dark for 2 hours. Thereafter, cells were fixed with 4% paraformaldehyde for 15 min. The cells were imaged using an inverted fluorescence microscope.

Cells were treated with colcemid (0.1 g/ml) (Gibco) at 37C for 2 hours, trypsinized, resuspended, and incubated in 0.075 M potassium chloride for 15 min at 37C, fixed with 3:1 methanol:acetic acid, and then dropped onto slides to spread the chromosomes. The chromosomes were visualized by Giemsa (Solarbio) staining.

All experiments were independently performed at least three times. The results are expressed as means SD. The data were analyzed by unpaired two-tailed Students t tests for comparisons of two groups and by one-way analysis of variance (ANOVA) with Tukeys test or Dunnetts multiple comparisons test for comparisons of multiple groups. All analyses were performed using SPSS Statistics 19.0 software. P < 0.05 was considered significant. The accession number for the RNA-seq data reported in this paper is National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO): GSE162889.

Acknowledgments: We thank D. Jiang and H. Liu for the computational analysis and H. Li for the support of transplantation in rabbit model. Funding: This study was supported by the Beijing Natural Science Foundation (Z200014), National Key R&D Program of China (2017YFA0105300), National Natural Science Foundation of China (81600749, 81790644, and 81970838), and Zhejiang Provincial Natural Science Foundation of China (LD18H120001LD). Author contributions: Z.-B.J. designed and supervised the study and provided financial supports. S.-H.P. and N.Z. performed transdifferentiation experiments and data analysis. N.Z. and X.F. conducted qRT-PCR experiments, N.Z. performed the reprogramming experiments and compound removal experiments, and X.F. performed the immunostaining. N.Z. worked on the in vivo experiments. Y.J. carried out corneal transparency scaling analysis. S.-H.P. wrote the manuscript. Z.-B.J. and Y.J. revised the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The Supplemental Information for this article includes seven figures, Supplemental Experimental Procedures, and a Small-Molecule Screening Table and can be found with this article online.

Follow this link:
Conversion of mouse embryonic fibroblasts into neural crest cells and functional corneal endothelia by defined small molecules - Science Advances

Global Stem Cells Market Regulations and Competitive Landscape Outlook, 2020 to 2025 The Courier – The Courier

Global Stem Cells Market 2020 by Company, Regions, Type and Application, Forecast to 2025 recently published by MarketQuest.biz, contains important market data that is collected from two or three sources, and the models. A loyal team of experienced forecasters, well-versed analysts, and knowledgeable researchers have worked painstakingly. The report involves six major parameters namely market analysis, market definition, market segmentation, key developments in the market, competitive analysis, and research methodology. Different markets, marketing strategies, future products, and emerging opportunities are taken into account while studying the global Stem Cells market and preparing this report.

The report presents a great understanding of the current market situation with the historic and upcoming market size based on technological growth, value and volume, projecting cost-effective and leading fundamentals in the market. The research report gives essential statistics on the market status of producers as well as offers beneficial advice and direction for businesses and individuals interested in the global Stem Cells industry.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/31756

Market Scope And Segments:

It provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. The global Stem Cells market is segmented on the basis of product, application, and leading regions. The report brings together granular experiences with enormous demand drivers, headway opportunities, pay prospects, and massive challenges and dangers that have a significant effect on the expansion of the company space.

The top players listed in the market report are:

CCBC, Beikebiotech, Vcanbio, Boyalife

Based on type, the report split into:

Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

Based on application market is segmented into:

Diseases Therapy, Healthcare

According to the regional segmentation, the market provides the information covers the following regions:

North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

This report aims to give emerging as well as established industry players a strategic edge by allowing them to better grasp industry events and gather insights on past and current industry happenings that are expected to affect the global Stem Cells markets growth in the coming years. The study provides an up-to-date overview of the emerging global business situation, as well as the most recent developments and factors, as well as the overall market climate. This report makes it easy to know about the market strategies that are being adopted by the competitors and leading organizations.

ACCESS FULL REPORT: https://www.marketquest.biz/report/31756/global-stem-cells-market-2020-by-company-regions-type-and-application-forecast-to-2025

The market study report can help to understand the market and strategize for business expansion. In the strategy analysis, the report throws light on insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the global Stem Cells industry.

The Market Research/analysis Report Contains Answers To Your Following Questions:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: sales@marketquest.biz Web: http://www.marketquest.biz

Here is the original post:
Global Stem Cells Market Regulations and Competitive Landscape Outlook, 2020 to 2025 The Courier - The Courier

Global cell isolation market was valued at USD7013.71 million in 2020 and is anticipated to reach USD15529.45 million by 2026 – Yahoo Finance

by registering a CAGR of 15. 25% until 2026. Cell isolation is a technique of isolating cells for diagnosis and analysis of a particular type of cell. The market growth can be attributed to the rising demand for drugs, vaccines and other related products, as they are manufactured with the assistance of cell isolation technique.

New York, June 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Isolation Market - Competition Forecast & Opportunities, 2026" - https://www.reportlinker.com/p06089447/?utm_source=GNW Increasing popularity of precision medicines is also working in the favor of the market growth.

Global cell isolation market has been segmented into product, cell type, source, technique, application, end-user, company and region.Based on technique, the market is further fragmented into centrifugation-based cell isolation, surface-marker based cell isolation and filtration-based cell isolation, amongst which, centrifugation-based cell isolation segment occupied the largest market share in 2020 as it finds extensive applications in various end user sectors such as academic institutes, research laboratories, etc.

Based on application, the market is further divided into biomolecule isolation, cancer research, stem cell research, in vitro diagnostics and others.Among these, cancer research and stem cell research are projected to be the lucrative segments of the market in the forecast period.

Increase in the research activities by biopharma companies and laboratory is the key factor for the growth of the segments.

Based on regional analysis, Asia-Pacific is expected to grow at the highest CAGR during the forecast period.The high CAGR of the region can be attributed to the relaxation in the stringent rules and regulations laid down by the government for drug development.

Another factor that can be held responsible for the fastest growth of the region is the availability of competent researchers and personnel who can carry out cell isolation techniques along with a wide genome pool.

Major players operating in the global cell isolation market include GE Healthcare Inc., Stemcell Technologies Inc., Danaher Corporation (Beckman Coulter Inc.), Becton, Dickinson and Company, Merck KGaA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Terumo Corporation, Sartorius AG, Cell Biolabs Inc., Miltenyi Biotec GmbH, F. Hoffmann-La Roche AG, Corning Inc, Akadeum Life Sciences, Inc., Invent Biotechnologies, Inc. and others. The market players are focusing on research and development activities in order to enhance their product portfolios and strengthen their position across the global market. For instance, the major pharmaceutical companies worldwide are making substantial investments in R&D to introduce new drugs in the market. Such investments are expected to increase the demand for cell isolation products over the coming years. In addition to this, new product developments help vendors to expand their product portfolio and gain maximum share in the sector. For example, Thermo Scientifics Medifuge is a benchtop centrifuge which is having a unique hybrid rotor as well as an interchangeable swing-out buckets and fixed-angle rotors to facilitate rapid & convenient applications on a single platform. Moreover, collaborations, mergers & acquisitions and regional expansions are some of the other strategic initiatives taken by major companies for serving the unmet needs of their customers.

Years considered for this report:

Historical Years: 2016-2019 Base Year: 2020 Estimated Year: 2021 Forecast Period: 2022-2026

Objective of the Study:

To analyze the historical growth in the market size of global cell isolation market from 2016 to 2020. To estimate and forecast the market size of global cell isolation market from 2021 to 2026 and growth rate until 2026. To classify and forecast global cell isolation market based on product, cell type, source, technique, application, end-user, company and region. To identify dominant region or segment in the global cell isolation market. To identify drivers and challenges for global cell isolation market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global cell isolation market. To conduct pricing analysis for global cell isolation market. To identify and analyze the profile of leading players operating in global cell isolation market. To identify key sustainable strategies adopted by market players in global cell isolation market. The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of companies and laboratories using cell isolation techniques across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the companies and laboratories using cell isolation techniques which could not be identified due to the limitations of secondary research. The analyst examined the companies and laboratories using cell isolation techniques and presence of all major players across the globe. The analyst calculated the market size of global cell isolation market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Companies and laboratories using cell isolation techniques, research labs, end users and other stakeholders Government bodies such as regulating authorities and policy makers Organizations, forums and alliances related to cell isolation Market research and consulting firms The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as research labs, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global cell isolation market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Global Cell Isolation Market, By Product: o Consumables o Instruments Global Cell Isolation Market, By Cell Type: o Human Cells o Animal Cells Global Cell Isolation Market, By Source: o Bone Marrow o Cord Blood/Embryonic Stem Cells o Adipose Tissue Global Cell Isolation Market, By Technique: o Centrifugation-Based Cell Isolation o Surface Marker-Based Cell Isolation o Filtration-Based Cell Isolation Global Cell Isolation Market, By Application: o Biomolecule Isolation o Cancer Research o Stem Cell Research o In Vitro Diagnostics o Others Global Cell Isolation Market, By End-User: o Biotechnology and Biopharmaceutical Companies o Research Laboratories and Institutes o Hospitals and Diagnostic Laboratories o Cell Banks Global Cell Isolation Market, By Region: o North America United States Mexico Canada o Europe Germany United Kingdom France Italy Spain o Asia-Pacific China Japan India South Korea Australia o South America Brazil Argentina Colombia o Middle East and Africa South Africa Saudi Arabia UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global cell isolation market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five). Read the full report: https://www.reportlinker.com/p06089447/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See more here:
Global cell isolation market was valued at USD7013.71 million in 2020 and is anticipated to reach USD15529.45 million by 2026 - Yahoo Finance